FindTrial
Sign In

EC-T

DRUG2 trials

Sponsors

Chinese Academy of Medical Sciences, Guangdong Provincial People's Hospital

Conditions

Breast Cancer

Phase 2

Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
CompletedNCT01150513
Chinese Academy of Medical SciencesBreast Cancer
Start: 2009-06-30End: 2016-04-30Updated: 2021-02-09
Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
NCT03507465
Guangdong Provincial People's HospitalBreast Cancer
Start: 2017-11-29End: 2020-11-29Target: 290Updated: 2018-04-25

Related Papers

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
Cancer Biology and Medicine2023-03-0211 citations
Abstract 5084: <i>KMT2D</i> and <i>PIK3CA</i> mutation as potential factors to predict adjuvant chemotherapy efficacy in surgical triple negative breast cancer
Cancer Research2022-06-151 citations
Abstract 5689: Effects of homologous recombination-related gene mutation subtypes on gene instability and the efficacy of platinum-containing regiments in triple-negative breast cancer
Cancer Research2022-06-15
Abstract P1-08-12: The status of homologous recombination deficiency is a potential biomarker for platinum-based chemotherapy in triple-negative breast cancer
Cancer Research2022-02-15
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up.
2021-10-1411 citations
Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.
Journal of Clinical Oncology2021-05-20
Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin) neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer.
Neoplasma2020-07-1310 citations
Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer.
Journal of Clinical Oncology2016-05-202 citations